Literature DB >> 507792

Anaerobic infection in cancer patients: comparative evaluation of clindamycin and cefoxitin.

J Klastersky, L Coppens, G Mombelli.   

Abstract

Clindamycin and cefoxitin with or without gentamicin were administered to cancer patients having localized infections presumably caused by anaerobic pathogens. The rates of favorable response were 89% in patients receiving clindamycine alone and 78% in patients receiving cefoxitin alone. When the total experience is considered (clindamycin or cefoxitin with and without gentamicin), 20 of 24 patients (83%) responded to clindamycin and 18 of 22 (82%) responded to cefoxitin. Both therapies were well tolerated. Clindamycin was found to be more effective than cefoxitin in eradicating the offending anaerobic pathogens from the site of infection. Aerobic pathogens were frequently isolated along with anaerobes from the infectious sites in this series; their susceptibility or resistance to clindamycin or cefoxitin did not influence the therapeutic response.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 507792      PMCID: PMC352862          DOI: 10.1128/AAC.16.3.366

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Treatment of anaerobic infections with lincomycin and clindamycin.

Authors:  J G Bartlett; V L Sutter; S M Finegold
Journal:  N Engl J Med       Date:  1972-11-16       Impact factor: 91.245

2.  "Bacteroides" bacteremia.

Authors:  J M Felner; V R Dowell
Journal:  Am J Med       Date:  1971-06       Impact factor: 4.965

3.  Cefoxitin and cephalothin: antimicrobial activity, human pharmacokinetics, and toxicology.

Authors:  W Brumfitt; J Kosmidis; J M Hamilton-Miller; J N Gilchrist
Journal:  Antimicrob Agents Chemother       Date:  1974-09       Impact factor: 5.191

4.  Anaerobic wound infections in cancer patients: comparative trial of clindamycin, tinidazole, and doxycycline.

Authors:  J Klastersky; M Husson; D Weerts-Ruhl; D Daneau
Journal:  Antimicrob Agents Chemother       Date:  1977-11       Impact factor: 5.191

5.  Cefoxitin: clinical evaluation in thirty-eight patients.

Authors:  P N Heseltine; D F Busch; R D Meyer; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1977-03       Impact factor: 5.191

6.  Comparative susceptibility of anaerobic bacteria to ticarcillin, cefoxitin, metronidazole, and related antimicrobial agents.

Authors:  D K Henderson; A W Chow; L B Guze
Journal:  Antimicrob Agents Chemother       Date:  1977-04       Impact factor: 5.191

  6 in total
  4 in total

Review 1.  Antibiotic trials in intra-abdominal infections. A critical evaluation of study design and outcome reporting.

Authors:  J S Solomkin; J L Meakins; M D Allo; E P Dellinger; R L Simmons
Journal:  Ann Surg       Date:  1984-07       Impact factor: 12.969

2.  The bacteriology of infected malignant ulcers.

Authors:  V O Rotimi; F A Durosinmi-Etti
Journal:  J Clin Pathol       Date:  1984-05       Impact factor: 3.411

3.  Moxalactam treatment of anaerobic infections in cancer patients.

Authors:  H Lagast; F Meunier-Carpentier; J Klastersky
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

4.  Anaerobic infections in cancer patients--a retrospective analysis of clindamycin, tinidazole, doxycycline, cefoxitin and lamoxactam.

Authors:  H Lagast; J Klastersky
Journal:  Infection       Date:  1982       Impact factor: 3.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.